[go: up one dir, main page]

PE20090890A1 - Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c - Google Patents

Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c

Info

Publication number
PE20090890A1
PE20090890A1 PE2008001216A PE2008001216A PE20090890A1 PE 20090890 A1 PE20090890 A1 PE 20090890A1 PE 2008001216 A PE2008001216 A PE 2008001216A PE 2008001216 A PE2008001216 A PE 2008001216A PE 20090890 A1 PE20090890 A1 PE 20090890A1
Authority
PE
Peru
Prior art keywords
ilmetil
dioxin
alkyl
dihidrobenzo
suptipo
Prior art date
Application number
PE2008001216A
Other languages
English (en)
Inventor
David Din Belle
Patrik Holm
Arto Karjalainen
Arto Tolvanen
Gerd Wohlfahrt
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39884455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090890(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Publication of PE20090890A1 publication Critical patent/PE20090890A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A COMPUESTOS DERIVADOS DE 1-(2,3-DIHIDROBENZO[1,4]DIOXIN-2-ILMETIL)AZACICLOS DE FORMULA I, DONDE X ES C(R5)(R6) O C(R7)(R8); R5 ES H O -OH, ENTRE OTROS; R6 ES FENILO OPCIONALMENTE SUSTITUIDO CON R9; R9 ES -OH, ALQUILO(C1-C6), ALQUENILO(C2-C6), ENTRE OTROS; R7 ES H, ALQUILO(C1-C6), ALCOXI(C1-C6), ENTRE OTROS; R8 ES -OH, ALQUILO(C1-C6), ALQUENILO(C2-C6), ENTRE OTROS; Z ES -[C(R4)2]N- O ENLACE SIMPLE; R4 ES H, -OH, ALQUENILO(C2-C6), ENTRE OTROS; R1 ES -OH, HALO, HALOALQUILO(C1-C6), ENTRE OTROS; R2 y R3 SON CADA UNO H O ALQUILO(C1-C6); m ES UN ENTERO DE 0-2; n ES 1 O 2. SON COMPUESTOS PREFERIDOS: 1-(2,3-DIHIDROBENZO[1,4]DIOXIN-2-ILMETIL)-5-FENIL-1,2,3,6-TETRAHIDROPIRIDINA, 1-(2,3-DIHIDROBENZO[1,4]DIOXIN-2-ILMETIL)-3-FENILPIPERIDINA, 1-(2,3-DIHIDROBENZO[1,4]DIOXIN-2-ILMETIL)-3-(2-METOXIFENIL)PIPERIDINA, ENTRE OTROS. SE REFIERE TAMBIEN A PROCEDIMIENTOS DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL SUPTIPO ADRENORECEPTOR ALFA2C, SIENDO UTILES PARA EL TRATAMIENTO ENFERMEDAD DE PARKINSON, DEPRESION, ESQUIZOFRENIA, ENTRE OTROS
PE2008001216A 2007-07-20 2008-07-17 Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c PE20090890A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95098307P 2007-07-20 2007-07-20

Publications (1)

Publication Number Publication Date
PE20090890A1 true PE20090890A1 (es) 2009-07-08

Family

ID=39884455

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001216A PE20090890A1 (es) 2007-07-20 2008-07-17 Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c

Country Status (31)

Country Link
US (3) US8492549B2 (es)
EP (1) EP2176252B1 (es)
JP (1) JP5460590B2 (es)
KR (1) KR101535059B1 (es)
CN (1) CN101842369B (es)
AR (1) AR069271A1 (es)
AU (1) AU2008278924B2 (es)
BR (1) BRPI0814529B8 (es)
CA (1) CA2693804C (es)
CL (1) CL2008002114A1 (es)
CO (1) CO6331473A2 (es)
CY (1) CY1115789T1 (es)
DK (1) DK2176252T3 (es)
EA (1) EA017554B1 (es)
ES (1) ES2502215T3 (es)
GE (1) GEP20125538B (es)
HR (1) HRP20141156T1 (es)
IL (1) IL202964A (es)
MA (1) MA31521B1 (es)
MY (1) MY153872A (es)
NZ (1) NZ582432A (es)
PE (1) PE20090890A1 (es)
PL (1) PL2176252T3 (es)
PT (1) PT2176252E (es)
RS (1) RS53571B1 (es)
SI (1) SI2176252T1 (es)
TN (1) TN2010000029A1 (es)
TW (1) TWI457122B (es)
UA (1) UA100695C2 (es)
WO (1) WO2009013390A1 (es)
ZA (1) ZA201000314B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI457122B (zh) 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
MX2010011498A (es) * 2008-04-29 2010-11-12 Nsab Af Neurosearch Sweden Ab Moduladores de neurotransmision de dopamina.
DK2271634T3 (da) 2008-04-29 2014-05-05 Integrative Res Lab Sweden Ab Modulatorer af dopamin-neurotransmission
EP2271635A1 (en) * 2008-04-29 2011-01-12 NSAB, Filial af NeuroSearch Sweden AB, Sverige Modulators of dopamine neurotransmission
TW201024282A (en) * 2008-11-20 2010-07-01 Orion Corp New pharmaceutical compounds
US20130267699A1 (en) 2011-06-24 2013-10-10 California Institute Of Technology Quaternary heteroatom containing compounds
US8822679B2 (en) 2011-06-24 2014-09-02 California Institute Of Technology Quaternary heteroatom containing compounds
US9518034B2 (en) 2013-10-14 2016-12-13 California Institute Of Technology Synthesis of chiral enaminones, their derivatives, and bioactivity studies thereof
US10421696B2 (en) 2014-12-18 2019-09-24 California Institute Of Technology Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation
CN105985389B (zh) * 2015-03-06 2019-03-19 北京大学 苯乙醇苷类似物及其合成方法和应用
EP3274342B1 (en) 2015-03-27 2022-05-04 California Institute of Technology Asymmetric catalytic decarboxylative alkyl alkylation using low catalyst concentrations and a robust precatalyst
TWI704145B (zh) 2015-06-05 2020-09-11 芬蘭商奧利安公司 新醫藥化合物
EP3426391A4 (en) 2016-03-11 2019-08-28 California Institute of Technology COMPOSITIONS AND METHODS FOR ACYLATING LACTAMEN
JP2019519582A (ja) * 2016-06-29 2019-07-11 オリオン コーポレーション ベンゾジオキサン誘導体およびその医薬用途
WO2018169818A1 (en) * 2017-03-12 2018-09-20 Xiaodong Wang Polycyclic amines as opioid receptor modulators
US10358422B2 (en) 2017-11-01 2019-07-23 California Institute Of Technology Methods for enantioselective allylic alkylation of esters, lactones, and lactams with unactivated allylic alcohols
GB201801130D0 (en) * 2018-01-24 2018-03-07 Univ Oxford Innovation Ltd Compounds
WO2020064479A1 (en) * 2018-09-25 2020-04-02 Bayer Aktiengesellschaft α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA
EP3699173A1 (en) 2018-10-18 2020-08-26 California Institute of Technology Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same
KR20240132346A (ko) 2022-01-07 2024-09-03 바이엘 악티엔게젤샤프트 수면 무호흡의 치료를 위한 α2-아드레날린수용체 서브타입 C 길항제
KR102776660B1 (ko) * 2022-01-25 2025-03-04 재단법인 한국파스퇴르연구소 벤조다이옥세인 유도체 화합물 및 이의 의약 용도

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2056046A (en) * 1933-05-19 1936-09-29 Rhone Poulenc Sa Manufacture of bases derived from benz-dioxane
US3635982A (en) 1969-04-08 1972-01-18 American Home Prod Amino-substituted-quinoxalinyloxazolidines and -oxazines
GB1411531A (en) * 1972-10-24 1975-10-29 Lafon Labor Amino derivatives of 1,4-benzodioxan
JPS5163193A (ja) * 1974-11-26 1976-06-01 Yoshitomi Pharmaceutical Tetorahidoropirazoropirijinkagobutsuno seizoho
US4039676A (en) * 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
US4329348A (en) * 1979-02-26 1982-05-11 Ciba-Geigy Corporation N-Oxacyclic-alkylpiperidines as psychostimulants
HU181575B (en) 1980-10-03 1983-10-28 Richter Gedeon Vegyeszet Process for preparing 3-chloro-propyl-malonic acid ester and cyano-acetic acid ester derivatives
FR2525600A1 (fr) * 1982-04-21 1983-10-28 Bouchara Emile Nouvelles carboxamidoguanidines, leur procede d'obtention et les compositions pharmaceutiques en renfermant
GB2167408B (en) 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
DD250930A1 (de) 1986-06-08 1987-10-28 Isis Chemie Zwickau Veb Verfahren zur herstellung neuer tetrahydroisochinolinderivate
US4957928A (en) * 1986-06-26 1990-09-18 Ciba-Geigy Corporation Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds
KR900701774A (ko) 1988-08-16 1990-12-04 제임스 제이. 플린 살진균성 벤조디옥산 아민 유도체
WO1992014453A1 (en) 1991-02-26 1992-09-03 Arc 1, Inc. Compositions and methods of treatment of sympathetically maintained pain
GB9318431D0 (en) * 1993-09-06 1993-10-20 Boots Co Plc Therapeutic agents
GB9514380D0 (en) * 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
FR2744451B1 (fr) 1996-02-01 1998-04-24 Pf Medicament Nouvelles imidazolidinones, pyrimidinones, et 1,3-diazepin-2 -ones, leur preparation et leurs applications en therapeutique
EP0983239A1 (en) 1997-05-06 2000-03-08 Novo Nordisk A/S Novel heterocyclic compounds
US5902807A (en) * 1997-05-12 1999-05-11 Antti Haapalinna Method for the treatment of mental illness in mammals and a composition therefor
DE69823868T2 (de) 1997-12-04 2005-04-21 Allergan Inc Substituierte imidazole derivate mit agonistischähnlicher wirkung auf die alpha 2b oder 2b/2c adrenergischen rezeptoren
FI20000480A0 (fi) 2000-03-01 2000-03-01 Orion Yhtymae Oyj Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina
AU2001290873B2 (en) * 2000-09-11 2006-07-27 Sepracor Inc. Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission)
CA2480695A1 (en) 2002-04-03 2003-10-09 Orion Corporation Polycyclic compounds as potent alpha2-adrenoceptor antagonists
WO2004067513A1 (en) 2003-01-27 2004-08-12 Oy Juvantia Pharma Ltd Antagonists for alpha-2 adrenoceptors
TWI457122B (zh) 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
JP5163193B2 (ja) 2008-03-13 2013-03-13 セイコーエプソン株式会社 プリンタシステム及びプリンタシステムにおける制御方法

Also Published As

Publication number Publication date
BRPI0814529A2 (pt) 2015-01-27
TWI457122B (zh) 2014-10-21
MY153872A (en) 2015-03-31
EA017554B1 (ru) 2013-01-30
PT2176252E (pt) 2014-12-03
MA31521B1 (fr) 2010-07-01
RS53571B1 (sr) 2015-02-27
KR101535059B1 (ko) 2015-07-24
BRPI0814529B8 (pt) 2021-05-25
AU2008278924A1 (en) 2009-01-29
US8697723B2 (en) 2014-04-15
US8492549B2 (en) 2013-07-23
CA2693804C (en) 2015-11-24
CO6331473A2 (es) 2011-10-20
KR20100044220A (ko) 2010-04-29
US8809536B2 (en) 2014-08-19
AU2008278924B2 (en) 2013-09-26
ES2502215T3 (es) 2014-10-03
WO2009013390A1 (en) 2009-01-29
CY1115789T1 (el) 2017-01-25
DK2176252T3 (en) 2014-12-08
HRP20141156T1 (hr) 2015-01-16
ZA201000314B (en) 2010-10-27
HK1148530A1 (en) 2011-09-09
IL202964A (en) 2013-12-31
SI2176252T1 (sl) 2014-12-31
US20140179926A1 (en) 2014-06-26
TW200908961A (en) 2009-03-01
CN101842369B (zh) 2014-01-22
CN101842369A (zh) 2010-09-22
UA100695C2 (ru) 2013-01-25
US20100216836A1 (en) 2010-08-26
TN2010000029A1 (en) 2011-09-26
EA201070169A1 (ru) 2010-06-30
JP2010534197A (ja) 2010-11-04
BRPI0814529B1 (pt) 2019-09-17
GEP20125538B (en) 2012-05-25
AR069271A1 (es) 2010-01-13
US20120035210A9 (en) 2012-02-09
PL2176252T3 (pl) 2015-04-30
NZ582432A (en) 2012-03-30
JP5460590B2 (ja) 2014-04-02
EP2176252A1 (en) 2010-04-21
US20130281486A1 (en) 2013-10-24
CA2693804A1 (en) 2009-01-29
EP2176252B1 (en) 2014-09-03
CL2008002114A1 (es) 2009-04-03

Similar Documents

Publication Publication Date Title
PE20090890A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
PE20090772A1 (es) Derivados de bencimidazol
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20080418A1 (es) Compuestos y composiciones como moduladores de la via de hedgehog
PE20080889A1 (es) Aminometil-4-imidazoles
PE20130647A1 (es) Indoles
PE20141120A1 (es) Compuestos heterociclicos
PE20081884A1 (es) Inhibidores heterociclicos de la aspartil proteasa
UY32547A (es) Piperidinas sustituidas como antagonistas de ccr3
PE20091621A1 (es) Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20091444A1 (es) Derivados de isoxazolo-pirazina
ECSP088511A (es) Agonistas del receptor del neuropeptido-2
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
AR077977A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
AR076460A1 (es) Antagonistas del receptor cxcr3
PE20071156A1 (es) COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA)
CL2012001366A1 (es) Compuestos derivados de carboxamida n-((2-morfolino-5-ariltiazol-4-il)metil), moduladores de receptores nicotinicos alfa 7; composicion farmaceutica; proceso para prepararla; combinacion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, demencia, esquizofrenia, enfermedad de parkinson, entre otras.
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp
PE20090620A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
PE20090655A1 (es) Derivados de 2-aza-biciclo[2.2.2]octano para prevencion o tratamiento de psicosis
PE20140968A1 (es) Derivados de benzamida sustituida

Legal Events

Date Code Title Description
FG Grant, registration